Esophagogastric Junction clinical trials at University of California Health
1 in progress, 0 open to eligible people
Showing trials for
Assessing Durvalumab and FLOT Chemotherapy in Resectable Gastric and Gastroesophageal Junction Cancer
Sorry, in progress, not accepting new patients
This is a Global Study of Neoadjuvant-Adjuvant Durvalumab or Placebo and FLOT Chemotherapy Followed by Adjuvant Durvalumab or Placebo in Patients with Resectable Gastric and Gastroesophageal Cancer (GC/GEJC) (MATTERHORN).
at UCLA
Our lead scientists for Esophagogastric Junction research studies include Zev Wainberg.
Last updated: